Comparative Pharmacology
Head-to-head clinical analysis: CHLORZOXAZONE versus PARAFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORZOXAZONE versus PARAFLEX.
CHLORZOXAZONE vs PARAFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Centrally acting muscle relaxant; inhibits polysynaptic reflexes at the spinal cord level, possibly by depressing the central nervous system.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
250-500 mg orally once daily, may increase to 500 mg twice daily if needed. Maximum 500 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Clinical Note
moderateChlorzoxazone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone propionate."
Clinical Note
moderateChlorzoxazone + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Sulfisoxazole
Terminal elimination half-life is approximately 2–3 hours, allowing for multiple daily dosing.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of an oral dose; fecal excretion accounts for about 20%.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Sulfisoxazole can be decreased when combined with Chlorzoxazone."